for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Wright Medical Group NV

WMGI.O

Latest Trade

30.30USD

Change

0.20(+0.66%)

Volume

1,611,111

Today's Range

30.07

 - 

30.37

52 Week Range

19.04

 - 

32.86

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Wright Medical Group NV Q2 Loss Per Share $0.15 From Continuing Operations

Aug 7 (Reuters) - Wright Medical Group NV <WMGI.O>::WRIGHT MEDICAL GROUP N.V. REPORTS 2019 SECOND QUARTER FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.15 FROM CONTINUING OPERATIONS.Q2 EARNINGS PER SHARE ESTIMATE $0.01 -- REFINITIV IBES DATA.Q2 SALES $230 MILLION VERSUS REFINITIV IBES ESTIMATE OF $233 MILLION.SEES FY 2019 SALES ABOUT $925 MILLION TO $930 MILLION.ANTICIPATES NON-GAAP ADJUSTED EBITDA FOR FULL-YEAR 2019 OF $157 MILLION TO $163 MILLION.SEES NON-GAAP ADJUSTED EARNINGS PER SHARE FOR FULL-YEAR 2019 TO BE $0.15 TO $0.20 PER DILUTED SHARE..FY2019 EARNINGS PER SHARE VIEW $0.22 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $961.1 MILLION -- REFINITIV IBES DATA.

Wright Medical Group Reports Q1 Loss Per Share $0.24 From Continuing Operations

May 7 (Reuters) - Wright Medical Group NV <WMGI.O>::WRIGHT MEDICAL GROUP N.V. REPORTS 2019 FIRST QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.24 FROM CONTINUING OPERATIONS.SEES FY 2019 SALES ABOUT $954 MILLION TO $966 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.01 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.17 TO $0.25 FROM CONTINUING OPERATIONS.Q1 SALES $230 MILLION VERSUS REFINITIV IBES ESTIMATE OF $195.4 MILLION.REITERATES 2019 ANNUAL GUIDANCE.

Wright Medical Group N.V. Reports Fourth Quarter Results, Provides 2019 Guidance

Feb 26 (Reuters) - Wright Medical Group NV <WMGI.O>::WRIGHT MEDICAL GROUP N.V. REPORTS 2018 FOURTH QUARTER AND FULL-YEAR FINANCIAL RESULTS AND PROVIDES 2019 ANNUAL GUIDANCE.Q4 LOSS PER SHARE $0.18 FROM CONTINUING OPERATIONS.SEES FY 2019 SALES ABOUT $954 MILLION TO $966 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.05 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.17 TO $0.25 FROM CONTINUING OPERATIONS.Q4 SALES $238 MILLION VERSUS REFINITIV IBES ESTIMATE OF $215.4 MILLION.SEES Q4 2018 SALES $238.1 MILLION.SEES Q4 2018 SALES UP 10.3 PERCENT.

Wright Medical Group NV Reports Q4 Loss Per Share $0.18 From Cont Ops

Feb 26 (Reuters) - Wright Medical Group NV <WMGI.O>::WRIGHT MEDICAL GROUP N.V. REPORTS 2018 FOURTH QUARTER AND FULL-YEAR FINANCIAL RESULTS AND PROVIDES 2019 ANNUAL GUIDANCE.REPORTS Q4 2018 SALES $238.1 MILLION.REPORTS Q4 2018 CONSTANT CURRENCY SALES GROWTH UP 10.3 PERCENT.Q4 LOSS PER SHARE $0.18 FROM CONTINUING OPERATIONS.SEES FY 2019 SALES ABOUT $954 MILLION TO $966 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.05 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.17 TO $0.25 FROM CONTINUING OPERATIONS.Q4 SALES $238 MILLION VERSUS REFINITIV IBES ESTIMATE OF $215.4 MILLION.

Wright Medical Group N.V. Sees Q4 2018 Sales Up 9.4 Pct

Jan 7 (Reuters) - Wright Medical Group NV <WMGI.O>::WRIGHT MEDICAL GROUP N.V. ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2018 NET SALES.SEES Q4 2018 SALES ABOUT $238.1 MILLION.SEES FY 2018 SALES ABOUT $836.2 MILLION.SEES FY 2018 SALES UP ABOUT 12.2 PERCENT.SEES Q4 2018 SALES UP 9.4 PERCENT.COMPANY REAFFIRMS PREVIOUSLY PROVIDED FY 2018 ADJUSTED EBITDA GUIDANCE.ALSO ANNOUNCED NEW THREE-YEAR FINANCIAL TARGETS FOR 2019 THROUGH 2021.TO DELIVER DOUBLE-DIGIT, CONSTANT CURRENCY NET SALES GROWTH EACH YEAR TARGETS FOR 2019 THROUGH 2021.TO MAINTAIN ADJUSTED GROSS MARGIN IN HIGH 70S% RANGE EACH YEAR FOR 2019 THROUGH 2021.EXPAND ADJUSTED EBITDA MARGIN TO MID-20% RANGE EXITING 2021.Q4 REVENUE VIEW $235.9 MILLION -- REFINITIV IBES DATA.FY2018 REVENUE VIEW $834.0 MILLION -- REFINITIV IBES DATA.SEES Q4 NET SALES INCLUDE NEGATIVE IMPACT OF FOUR FEWER SELLING DAYS IN Q4 OF 2018.ESTIMATES NEGATIVE IMPACT ON Q4 NET SALES TO BE APPROXIMATELY $9 MILLION.

Wright Medical Group N.V. Announces Organizational Changes

Jan 7 (Reuters) - Wright Medical Group NV <WMGI.O>::WRIGHT MEDICAL GROUP N.V. ANNOUNCES ORGANIZATIONAL CHANGES TO FURTHER DRIVE LONG-TERM GROWTH AND PROFITABILITY.WRIGHT MEDICAL - KEVIN CORDELL, CURRENT PRESIDENT, U.S., PROMOTED TO NEW POSITION OF EXECUTIVE VICE PRESIDENT, CHIEF GLOBAL COMMERCIAL OFFICER.WRIGHT MEDICAL - LANCE BERRY, CURRENT SENIOR VP AND CFO, BEING PROMOTED TO NEW POSITION OF EXECUTIVE VP, CHIEF FINANCIAL AND OPERATIONS OFFICER.

Wright Medical Announces Private Placement Of Cash Convertible Senior Notes

June 21 (Reuters) - Wright Medical Group NV <WMGI.O>::WRIGHT MEDICAL GROUP N.V. ANNOUNCES PRIVATE PLACEMENT OF $675 MILLION OF 1.625% CASH CONVERTIBLE SENIOR NOTES DUE 2023.WRIGHT MEDICAL - ESTIMATES THAT PROCEEDS OF ISSUANCE WILL BE ABOUT $200 MILLION, AFTER DEDUCTING ESTIMATED FEES AND EXPENSES PAYABLE BY CO.WRIGHT MEDICAL-SOME INVESTORS,CURRENTLY HOLDING CO'S CONVERTIBLE NOTES DUE 2020 TO EXCHANGE ABOUT $401 MILLION EXISTING NOTES FOR ABOUT $460 MILLION OF NOTES.WRIGHT - IN CONNECTION WITH NOTES ISSUANCE, CO & UNIT ENTERED INTO PRIVATELY NEGOTIATED CASH CONVERTIBLE NOTE HEDGE DEALS WITH CERTAIN INSTITUTIONS.

Wright Medical Group Announces FDA Premarket Approval For Augment Injectable Bone Graft

June 13 (Reuters) - Wright Medical Group NV <WMGI.O>::WRIGHT MEDICAL GROUP N.V. ANNOUNCES FDA PREMARKET APPROVAL FOR AUGMENT® INJECTABLE BONE GRAFT.WRIGHT MEDICAL GROUP NV - COMPANY CAN NOW INITIATE COMMERCIAL SALE AND DISTRIBUTION IN U.S..WRIGHT MEDICAL GROUP NV - COMPANY PLANS TO UPDATE 2018 GUIDANCE ON ITS Q2 EARNINGS CALL ON AUGUST 8, 2018.WRIGHT MEDICAL GROUP NV - WILL IMMEDIATELY START PROCESS OF FINALIZING ITS PACKAGING CARRYING FDA APPROVED LABELING.WRIGHT MEDICAL GROUP NV - EXPECTS TO BEGIN SELLING PRODUCT IN U.S. SHORTLY AND COMPLETE ROLLOUT IN NEXT FOUR TO SIX WEEKS.

Wright Medical Group ‍Q4 Net Sales $218 Million​

Feb 27 (Reuters) - Wright Medical Group Nv <WMGI.O>::WRIGHT MEDICAL GROUP N.V. REPORTS 2017 FOURTH QUARTER AND FULL-YEAR FINANCIAL RESULTS AND PROVIDES 2018 ANNUAL GUIDANCE.Q4 EARNINGS PER SHARE $0.25 FROM CONTINUING OPERATIONS.SEES FY 2018 SALES ABOUT $800 MILLION TO $812 MILLION.SEES Q4 2017 SALES $217.6 MILLION.SEES Q4 2017 SALES UP 11.2 PERCENT.‍Q4 2017 NET SALES OF $218 MILLION​.

Wright Medical Group Reports Q4 EPS $0.25 From Cont Ops

Feb 27 (Reuters) - Wright Medical Group Nv <WMGI.O>::WRIGHT MEDICAL GROUP N.V. REPORTS 2017 FOURTH QUARTER AND FULL-YEAR FINANCIAL RESULTS AND PROVIDES 2018 ANNUAL GUIDANCE.REPORTS Q4 2017 SALES $217.6 MILLION.REPORTS Q4 2017 SALES UP 11.2 PERCENT.Q4 EARNINGS PER SHARE $0.25 FROM CONTINUING OPERATIONS.SEES FY 2018 SALES ABOUT $800 MILLION TO $812 MILLION.‍Q4 2017 NET SALES OF $218 MILLION​.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up